0001734005 2026-08-28 2026-08-28 0001734005 1 2026-08-28 2026-08-28 0001734005 2 2026-08-28 2026-08-28 0001734005 3 2026-08-28 2026-08-28 0001734005 4 2026-08-28 2026-08-28 0001734005 5 2026-08-28 2026-08-28 0001734005 6 2026-08-28 2026-08-28 0001734005 7 2026-08-28 2026-08-28 0001734005 1 2026-08-28 2026-08-28 0001734005 2 2026-08-28 2026-08-28 iso4217:USD pure S-3 S-3 EX-FILING FEES 0001734005 Niki BioSolutions, Inc. N/A 0.0001381 0.0001381 0.0001381 0.0001381 0.0001381 0.0001381 true false S-3 Niki BioSolutions, Inc. false Equity Class A Ordinary Shares, par value $0.00001per share true 0.00 false Equity Preferred Stock true 0.00 false Debt Debt Securities true 0.00 false Equity Warrants true 0.00 false Other Subscription Rights true 0.00 false Other Units true 0.00 false Unallocated (Universal) Shelf true 75000000.00 0.0001381 10357.50 75000000.00 10357.50 0.00 8265.00 2092.50 Securities registered hereunder may be sold separately, together or as units with other securities registered hereunder. The registrant is registering an indeterminate number of securities for offer and sale from time to time at indeterminate prices, which shall have an aggregate offering price not to exceed $75,000,000. In addition, pursuant to Rule 416(a) under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional number of securities that may be issued from time to time to prevent dilution as a result of a distribution, split, combination, or similar transaction. Securities registered hereunder may be sold separately, or together with other securities registered hereunder. Includes consideration to be received by the registrant, if applicable, for registered securities that are issuable upon exercise, conversion, or exchange of other registered securities. The proposed maximum aggregate offering price per class of security will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered hereunder and is not specified as to each class of security pursuant to Instructions to the Calculation of Filing Fee Tables and Related Disclosure (2)(A)(iii)(b) of Form F-3 under the Securities Act. Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(o) under the Securities Act. true F-3 333-292793 2026-01-16 8265.00 true Niki BioSolutions, Inc. F-3 333-292793 2026-01-16 8265.00 Pursuant to Rule 415(a)(6) under the Securities Act, the registrant hereby carries forward unsold securities previously registered with a proposed maximum aggregate offering price of $75,000,000 (the "Offset Securities") under the registrant's prior registration statement on Form F-3 (Filer No. 333-292793) which was filed on January 16,2026 (the "Prior Registration Statement"). The Prior Registration Statement registered securities for a maximum aggregate offering price of $75,000,000, but did not sell any of the securities registered therein. In connection with the filing of the Prior Registration Statement, the registrant paid a filing fee of $8,265, calculated in accordance with Rule 457(o) under the Securities Act. The filing fees associated with the Offset Securities shall hereby offset the filing fees due with this current filing. . Pursuant to Rule 415(a)(6), the offering of the Offset Securities under the Prior Registration Statement will be deemed terminated as of the date of effectiveness of this registration statement.